drugset / Trial / NCT06876636
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
Exploring the efficacy and safety of zoledronic acid combined with neoadjuvant chemotherapy (EC-T) in neoadjuvant treatment for early-stage or locally advanced triple-negative breast cancer, the trial protocol of zoledronic acid + liposomal doxorubicin + cyclophosphamide followed by zoledronic acid + nab-paclitaxel will provide a new effective therapeutic strategy for neoadjuvant treatment of triple-negative breast cancer patients and offer a novel treatment approach for triple-negative breast cancer.
Timeline
- Start
- 2025-03-10
- Primary completion
- 2025-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 4 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 35 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Background | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Background | Toripalimab | Monoclonal antibody | 240 mg | — |